Therapy Areas: Oncology
Thor Medical signs three-year isotope supply agreement with Medicines Discovery Catapult
27 October 2026 - Thor Medical ASA (OSE:TRMED), a supplier of alpha-emitters for precision cancer treatment, said on Tuesday that it has signed a three-year supply agreement with Medicines Discovery C...
Enhertu wins EU approval for HER2-positive early breast cancer treatment
27 October 2026 - Biopharmaceutical company AstraZeneca plc (LSE/STO/NYSE: AZN) and its Japanese pharmaceutical partner Daiichi Sankyo (TYO: 4568) said on Tuesday that the European Commission has appr...
Riboscience reports Phase 1a/b overall survival data for ENPP1 inhibitor RBS2418
27 October 2026 - Clinical-stage biotechnology company Riboscience LLC announced on Monday the presentation of initial overall survival (OS) and immune activation data from the Phase 1a/b clinical tri...
Citius Oncology reports growth in LYMPHIR unit shipments to US wholesalers
27 October 2026 - Oncology-focused biopharmaceutical company Citius Oncology Inc (Nasdaq:CTOR), a majority-owned subsidiary of Citius Pharmaceuticals Inc (Nasdaq:CTXR), announced on Monday preliminary...
Genmab reports 28.2-month median overall survival with petosemtamab combination in Phase 2 trial
26 October 2026 - Danish biotechnology company Genmab A/S (CPH:GMAB) on Monday reported updated Phase 2 results showing median overall survival of 28.2 months with investigational petosemtamab plus pe...
Akeso presents Phase III HARMONi-GI1 trial results in biliary tract cancer at ESMO 2026
26 October 2026 - Chinese biopharmaceutical company Akeso Inc (HKEX:9926) announced on Sunday the presentation of results from the randomised, controlled, double-blind, multicentre, registrational Pha...